Connect Biopharma (NASDAQ:CNTB) Upgraded by Piper Sandler to “Strong-Buy” Rating

Posted by Geri Gentry on Jun 27th, 2026

Connect Biopharma (NASDAQ:CNTB – Get Free Report) was upgraded by stock analysts at Piper Sandler to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on CNTB. Weiss Ratings restated a “sell (d)” rating on shares of Connect Biopharma in a research report on Monday, May 4th. Canaccord Genuity Group began coverage on shares of Connect Biopharma in a research note on Tuesday, May 26th. They issued a “buy” rating and a $6.00 price target for the company. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Connect Biopharma in a report on Tuesday, March 31st. Wall Street Zen raised shares of Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Connect Biopharma in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Connect Biopharma presently has a consensus rating of “Buy” and an average price target of $7.17.

View Our Latest Report on CNTB

Connect Biopharma Stock Up 6.5%

Shares of NASDAQ:CNTB opened at $2.21 on Friday. Connect Biopharma has a 52-week low of $0.96 and a 52-week high of $3.82. The stock has a market cap of $138.84 million, a P/E ratio of -1.92 and a beta of -0.22. The business has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.52. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.01.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.05). The firm had revenue of $0.02 million during the quarter. On average, research analysts expect that Connect Biopharma will post -1 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director James Huang acquired 150,000 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were acquired at an average price of $2.48 per share, with a total value of $372,000.00. Following the completion of the transaction, the director owned 13,310,000 shares of the company’s stock, valued at $33,008,800. The trade was a 1.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 22.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Connect Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in CNTB. Bank of America Corp DE acquired a new position in shares of Connect Biopharma during the first quarter worth about $41,000. ADAR1 Capital Management LLC acquired a new stake in Connect Biopharma in the first quarter valued at approximately $1,945,000. Knott David M Jr raised its holdings in Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after acquiring an additional 187,835 shares in the last quarter. Simplify Asset Management Inc. purchased a new position in Connect Biopharma in the first quarter worth approximately $135,000. Finally, Perceptive Advisors LLC purchased a new position in Connect Biopharma in the fourth quarter worth approximately $2,235,000. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.